Journal Article

© 2015 Prous Science, S.A.U. or its licensors. All rights reserved. The TGF-b superfamily receptor activin receptor-like kinase 1 (ALK-1) has essential roles in regulating angiogenesis during development and homeostasis, as well as pathophysiological tumor angiogenesis. Dalantercept is a soluble chimeric protein composed of the ALK-1 extracellular domain fused to the human Fc domain. Dalantercept acts as a ligand trap to prevent the activation of endogenous ALK-1 by bone morphogenetic proteins 9/10. In preclinical models, dalantercept inhibits tumor growth and enhances the efficacy of cytotoxic chemotherapy. In early clinical development, dalantercept as a single agent has had a promising disease control rate. Dalantercept has a favorable safety profile, with fluid retention and edema being the most common side effects. Current studies are investigating the role of dalantercept with cytotoxic chemotherapy and other targeted therapies.

Full Text

Duke Authors

Cited Authors

  • Hector-Greene, ME; Blobe, GC

Published Date

  • October 1, 2015

Published In

Volume / Issue

  • 40 / 10

Start / End Page

  • 633 - 637

International Standard Serial Number (ISSN)

  • 0377-8282

Digital Object Identifier (DOI)

  • 10.1358/dof.2015.040.10.2386993

Citation Source

  • Scopus